Nasdaq Innovation

Big Beautiful Boycott: Can It Really Hurt Coca-Cola, Amazon, and Kraft Heinz Stocks?Kraft Heinz (NASDAQ:KHC) expects organic net sales to be relatively flat in 2027 as it continues a turnaround built on higher investment in marketing, product development and innovation. The compa

Falling Fast, Rising Soon? 3 Stocks With Upside AheadAllot (NASDAQ:ALLT) reported third-quarter revenue growth of 16% and raised the midpoint of its full-year revenue outlook, as its security-as-a-service business expanded and existing customers placed orders for its SMART produc

Legal Issues Behind It, IBIO Stock May Be a Long Play For Risk-Tolerant Investors iBio (NASDAQ:IBIO) expects to report initial data from its clinical-stage myostatin program in the first quarter of the next calendar year and begin dosing patients in a separate Activin E study du

5 Stocks to Buy in November: Bargains Worth Giving Thanks ForAmprius Technologies (NYSE:AMPX) raised its 2026 revenue target for the third consecutive quarter after reporting record third-quarter sales, but lowered its adjusted EBITDA outlook as it invests in product development,

Neo Performance Materials (TSE:NEO) raised its full-year 2026 earnings outlook after reporting a sharp increase in third-quarter revenue and adjusted earnings, as demand and pricing strengthened across its rare earth magnetics and critical materials businesses. The company now e

Pharma Frenzy: Volatility Ignites Biotech SectorTonix Pharmaceuticals (NASDAQ:TNXP) said sales of its fibromyalgia treatment TONMYA rose 37% in the third quarter, as the company expanded insurance access and increased its sales force. Chief Executive Seth Lederman told biopharma

2 gene-editing stocks reshaping hereditary disease treatments Editas Medicine (NASDAQ:EDIT) expects to dose the first patients this year in a Phase I/II study of its lead gene-editing candidate, EDIT-401, as the company focuses its development strategy on in vivo CRISPR therapies

3 Top-Performing U.S.-Traded Emerging Market Stocks in 2024Credicorp (NYSE:BAP) reported a 19.9% return on equity for the third quarter of 2026 as lending and transaction activity grew, while the financial group increased provisions for potential El Niño-related losses. Executiv

MaxCyte: Building the Future of Cell and Gene Therapy InnovationMaxCyte (NASDAQ:MXCT) reported 49% third-quarter revenue growth and raised its 2026 revenue outlook, while announcing an agreement to acquire cell therapy materials supplier Akron Bio for $151.8 million. The transac

3 AI Infrastructure Plays Beyond ChipmakersVertiv (NYSE:VRT) is seeing faster growth in its global project pipeline as demand for artificial intelligence and traditional cloud computing continues to expand, CEO Gio Albertazzi said during a discussion with Baird analyst Luke Junk.

Celldex Therapeutics (NASDAQ:CLDX) plans to submit a biologics license application for barzolvolimab in 2027, using full 52-week data from its Phase 3 studies in chronic spontaneous urticaria, executives said at Guggenheim’s 3rd Annual Healthcare Innovation Conference. The compa

Magic Mushrooms, Hard Cash: Compass Pathways’ Trial Win, Fast RaiseHelus Pharma expects results from the first Phase III trial of its experimental adjunctive treatment for major depressive disorder later this quarter, CEO Michael Halstead said at the Guggenheim Healthcare Innovat

Strike a Balance Between Growth and Stability With These 3 Names Ready to RallyOnto Innovation (NYSE:ONTO) reported third-quarter revenue of $410 million, up 19% from the previous quarter and nearly 90% from a year earlier, as demand for semiconductor inspection and metrology equ

Biotech Is Heating Up—These 2 Red-Hot Stocks Stand OutAxsome Therapeutics (NASDAQ:AXSM) reported $260 million in third-quarter revenue, driven by growth in its AUVELITY treatment for major depressive disorder and Alzheimer’s disease agitation, executives said at the Guggenheim He

Better Home & Finance (NASDAQ:BETR) reported third-quarter revenue below its guidance and outlined plans to cut costs, expand home-equity lending and use artificial intelligence to improve productivity as it pursues adjusted EBITDA break-even. The mortgage lender reported $45.1

Corbus Pharmaceuticals stock: An explosive 342% YTD surgeCorbus Pharmaceuticals (NASDAQ:CRBP) has started a Phase 3 study of its cancer drug CRB-701 and expects an exploratory readout from a separate frontline combination study in the first quarter of next year, CEO Yuval Cohen s

Brutal 2025 for Sarepta—Analysts Still Call for 179% UpsideSarepta Therapeutics (NASDAQ:SRPT) expects updates from its experimental neuromuscular disease programs to help shape its next phase of growth, while relying on its Duchenne muscular dystrophy business to fund development

Biotech & Healthcare Meet AI: Stocks Soar On Innovation PotentialRadNet (NASDAQ:RDNT) reported record third-quarter revenue and adjusted EBITDA as demand for advanced imaging, acquisitions and growth in its Digital Health business helped drive results. The company also raised its

MarketBeat Week in Review – 06/08 - 06/12GSK (NYSE:GSK) is advancing a portfolio of long-acting medicines and combination treatments for respiratory and inflammatory diseases, with a particular focus on chronic obstructive pulmonary disease, a senior research executive said at Gu

3 Biopharmaceutical Stocks Bucking the Sell-OffDBV Technologies (NASDAQ:DBVT) is preparing for a potential U.S. launch of its peanut allergy patch for children ages 4 to 7 while awaiting a decision on whether regulators will accept its biologics license application, executives sa